Inj, valproate sod, 5 mg
Products billed under this code include Valproate Sodium.
Payment limit per 5 MG, by effective quarter, 1Q26 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under J3379
From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Valproate Sodium | Hikma Pharmaceuticals USA Inc. | 00143-9637-10 | 1000 | $32.00 |
| Valproate Sodium | Hikma Pharmaceuticals USA Inc. | 00143-9785-10 | 1000 | $32.00 |
| Valproate Sodium | Sagent Pharmaceuticals | 25021-0797-05 | 1000 | $32.00 |
| Valproate Sodium | FreseniUS Kabi USA, LLC | 63323-0494-05 | 1000 | $32.00 |
| Valproate Sodium | FreseniUS Kabi USA, LLC | 63323-0494-16 | 1000 | $32.00 |
Every quarter
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $0.032 | +$0.018 | 5 MG | Inj, valproate sod, 5 mg | v1, posted September 17, 2026 |
| 3Q26 | $0.014 | −$0.026 | 5 MG | Inj, valproate sod, 5 mg | v1, posted September 15, 2026 |
| 2Q26 | $0.04 | −$0.005 | 5 MG | Inj, valproate sod, 5 mg | v1, posted September 15, 2026 |
| 1Q26 | $0.045 | – | 5 MG | Inj, valproate sod, 5 mg | v1, posted September 15, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
CMS source files
- 4Q26: 2026-09-17_october-2026-medicare-part-b-payment-limit-files-final.zipposted September 17, 2026
- 4Q26: 2026-09-17_october-2026-ndc-hcpcs-crosswalk-final.zipposted September 17, 2026
- 3Q26: 2026-09-15_july-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026
- 2Q26: 2026-09-15_april-2026-medicare-part-b-payment-limit-files-final-file.zipposted September 15, 2026
- 1Q26: 2026-09-15_january-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026